| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Virus-like particles |
| Clinical data | |
| Routes of administration | Oral |
MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development |
| ||||||||||
| Classes |
| ||||||||||
| Administration |
| ||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers |
| ||||||||||
| Controversy |
| ||||||||||
| Related |
| ||||||||||
| |||||||||||
Viruses
COVID-19
 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccinesorvaccination is a stub. You can help Wikipedia by expanding it. |
